4166-53-4

Basic information

• Product Name: 3-METHYLGLUTARIC ANHYDRIDE
• Synonyms: 2H-Pyran-2,6(3H)-dione, dihydro-4-methyl-;BETA-METHYLGLUTARIC ANHYDRIDE;4-METHYLDIHYDRO-2H-PYRAN-2,6(3H)-DIONE;4-METHYL-DIHYDRO-PYRAN-2,6-DIONE;3-METHYLGLUTARIC ANHYDRIDE;3-Methylglutaricanhydride,98%;3,4-Dihydro-4β-methyl-2H-pyran-2,6(5H)-dione;3-Methylpentanedioic anhydride
• CAS NO: 4166-53-4
• Molecular Formula: C₆H₈O₃
• Molecular Weight: 128.13
• EINECS: 224-020-6
• Product Categories: Anhydride Monomers;Monomers;Polymer Science
• Mol File: 4166-53-4.mol
• Article Data: 15

Chemical Properties

• Melting Point: 42-46 °C(lit.)
• Boiling Point: 180-182 °C25 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: White/Crystalline Low Melting Solid
• Density: 1.2072 (rough estimate)
• Vapor Pressure: 0.00119mmHg at 25°C
• Refractive Index: 1.4585 (estimate)
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• Sensitive: Moisture Sensitive
• Stability: Moisture Sensitive
• BRN: 114457
• CAS DataBase Reference: 3-METHYLGLUTARIC ANHYDRIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHYLGLUTARIC ANHYDRIDE(4166-53-4)
• EPA Substance Registry System: 3-METHYLGLUTARIC ANHYDRIDE(4166-53-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• F: 10-21
• Hazardous Substances Data: 4166-53-4(Hazardous Substances Data)

Usage

Chemical Properties

WHITE CRYSTALLINE LOW MELTING SOLID

Uses

3-?Methylglutaric Anhydride is a reagent used in the synthesis of oxoeicosanoid receptor antagonists which are involved in mediating stimulatory effects on cell types involved in mediating immunity-based inflammatory reactions.

InChI:InChI=1/C6H8O3/c1-4-2-5(7)9-6(8)3-4/h4H,2-3H2,1H3

Upstream product

• 67-56-1 methanol 
• 626-51-7 3-methyl glutaric acid 
• 141-82-2 malonic acid 
• 123-63-7 paracetaldehyde 
• 5832-70-2 diethyl 2-cyano-3-methylpentanedioate 
• 4161-07-3 3-Methyl-glutarsaeure-mono--ester 
• 6280-15-5 3-methylpentanedial 

Downstream Products

• 27151-65-1 3-methyl-1,5-pentanedioic acid monomethyl ester 
• 25883-04-9 3-(Acetyl-methyl-amino)-5-(4-carboxy-3-methyl-butyrylamino)-2,4,6-triiodo-benzoic acid 
• 4962-66-7 N-(3,4-Dimethoxyphenaethyl)-β-methylglutarsaeure monoamid) 
• 92864-22-7 5-(2,4-Dimethyl-phenyl)-3-methyl-5-oxo-pentanoic acid 
• 63473-60-9 (R)-3-methylpentanedioic acid monomethyl ester 
• 63473-60-9 (S)-5-methoxy-3-methyl-5-oxopentanoic acid 
• 99414-58-1 5-(4-Cyclohexyl-phenyl)-3-methyl-5-oxo-pentanoic acid 
• 99414-56-9 5-(3-Chloro-4-methoxy-phenyl)-3-methyl-5-oxo-pentanoic acid 
• 128684-35-5 4-((R)-1-Methoxycarbonyl-2-phenyl-ethylcarbamoyl)-3-methyl-butyric acid 
• 88336-90-7 2-[3(RS)-methyl-1-oxo-5-hydroxypentanoyl]-5-(6-phenylhexyl)thiophene 
• 141329-93-3 (R)-3-Methyl-pentanedioic acid mono-((S)-4,4,4-trifluoro-3-hydroxy-1-phenyl-3-trifluoromethyl-butyl) ester 
• 141329-93-3 (S)-3-Methyl-pentanedioic acid mono-((S)-4,4,4-trifluoro-3-hydroxy-1-phenyl-3-trifluoromethyl-butyl) ester 
• 84258-52-6 2-methyl-4-oxo-piperidino<1,2-a>benzimidazole 
• 84258-51-5 1,3-bis(benzimidazol-2-yl)-2-methylpropane 

Relevant articles and documents

Total Synthesis of Huperzine R

A total synthesis of huperzine R was accomplished. Intramolecular cycloaddition of a nitrile oxide and reductive cleavage of the resulting isoxazoline induced sequential cleavage of the C-C and C-O bonds to form the characteristic bicyclic lactam core with an enone moiety. Construction of the butenolide moiety from the enone afforded huperzine R.

LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

LIPID PRODRUGS OF BTK INHIBITORS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.